Non-alcoholic fatty liver disease and cardiovascular disease

Atherosclerosis

Volumn 224, Issue 2, 2012, Pages 324-325

  Santos, Raul D ^a   Agewall, Stefan ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; EXERCISE; HUMAN; LIPID STORAGE; NONALCOHOLIC FATTY LIVER; NOTE; PRIORITY JOURNAL; WEIGHT REDUCTION;

ASIAN CONTINENTAL ANCESTRY GROUP; CAROTID ARTERY DISEASES; FATTY LIVER; FEMALE; HUMANS; MALE;

EID: 84866538988     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.07.018     Document Type: Note

References (19)

1. Preiss D., Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008, 115:141-150.
2. Ahmed M.H., Abu E.O., Byrne C.D. Non-alcoholic fatty liver disease (nafld): new challenge for general practitioners and important burden for health authorities?. Prim Care Diabetes 2010, 4:129-137.
3. Day C.P. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 2005, 129:375-378.
4. Fassio E., Alvarez E., Dominguez N., Landeira G., Longo C. Natural history of non-alcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004, 40:820-826.
5. Ndumele C.E., Nasir K., Conceiçao R.D., Carvalho J.A., Blumenthal R.S., Santos R.D. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol 2011, 31:1927-1932.
6. Carvalho J.A., Barengo N.C., Tuomilehto J., Conceição R.D., Santos R.D. The finnish diabetes risk score (FINDRISC) as a screening tool for hepatic steatosis. Ann Med 2011, 43:487-494.
7. Li X., Mingfeng X., Ma H., et al. Liver fat content is associated with increased carotid atherosclerosis in Chinese middle-agedand elderly population: Shanghai Changfeng study. Atherosclerosis 2012, 224(2):480-485.
8. Agewall S., Degroot E., Marcos-Alberca P., et al. Ultrasound and radiology surrogate endpoints in pharmacological studies. Atherosclerosis 2012 May 7, [Epub ahead of print].
9. Xia M.F., Yan H.M., He W.Y., et al. Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method. Obesity (Silver Spring) 2012, 20:444-452.
10. Chen C.H., Nien C.K., Yang C.C., Yeh Y.H. Association between nonalcoholic fatty liver disease and coronary artery calcification. Dig Dis Sci 2010, 55:1752-1760.
11. Akabame S., Hamaguchi M., Tomiyasu K., et al. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). Circ J 2008, 72:618-625.
12. Sookoian S., Pirola C.J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008, 49:600-607.
13. Schindhelm R.K., Diamant M., Bakker S.J., et al. Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus. Eur J Clin Invest 2005, 35:369-374.
14. Villanova N., Moscatiello S., Ramilli S., et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005, 42:473-480.
15. Targher G., Bertolini L., Rodella S., et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007, 30:2119-2121.
16. Haring R., Wallaschofski H., Nauck M., Dorr M., Baumeister S.E., Volzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009, 50:1403-1411.
17. Korenblat K.M., Fabbrini E., Mohammed B.S., Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008, 134:1369-1375.
18. Musso G., Cassader M., Rosina F., Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012, 55:885-904.
19. Chan D.C., Watts G.F., Gan S.K., Ooi E.M., Barrett P.H. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 2010, 33:1134-1139.